Manabe A, Tsuchida M, Hanada R, Ikuta K, Toyoda Y, Okimoto Y, Ishimoto K, Okawa H, Ohara A, Kaneko T, Koike K, Sato T, Sugita K, Bessho F, Hoshi Y, Maeda M, Kinoshita A, Saito T, Tsunematsu Y, Nakazawa S
Tokyo Children's Cancer Study Group, Japan.
J Clin Oncol. 2001 Jul 1;19(13):3182-7. doi: 10.1200/JCO.2001.19.13.3182.
To determine the effects of eliminating initial lumbar punctures in 418 consecutively treated children with acute lymphoblastic leukemia (ALL).
Patients were enrolled onto a trial conducted in central Japan between 1989 and 1992. Treatment consisted of standard four-drug induction therapy followed by a risk-based intensification phase, reinduction therapy, late intensification, and remission maintenance therapy (total of 104 weeks). The initial lumbar puncture, with an intrathecal injection of chemotherapy, was performed after 1 week of prednisolone sensitivity testing (day 8). End points included response to prednisolone, CNS status at the time of the day 8 lumbar puncture, subsequent adverse events in CNS and bone marrow, and event-free survival (EFS).
The remission induction rate was 93.1% with a 6-year EFS rate (+/- SE) of 68.7% +/- 2.4%, which is similar to historical results for patients who received their diagnostic lumbar puncture and first instillation of intrathecal chemotherapy on day 0. Overall, 84.5% of the patients had good responses to prednisolone, whereas 15.5% had poor responses. Clinical outcome was strikingly better for the good responders (6-year EFS, 74.1% +/- 2.5% compared with 40.1% +/- 6.4% for patients with poor responses), suggesting that omission of intrathecal chemotherapy did not alter the predictive value of drug sensitivity testing. Eighteen patients experienced CNS relapse as their first adverse event (cumulative risk, 5.1%; 95% confidence interval, 2.7% to 7.4%), coincident with reports from groups using conventional strategies of CNS clinical management. Bleeding into the CSF at the time of the day 8 lumbar puncture was apparent in 29 cases (8.1%), but leukemic blasts were identified in only two.
Delay of the initial lumbar puncture and intrathecal injection of chemotherapy seems to be feasible in children with ALL. Further controlled evaluations are needed to establish the validity of this conclusion.
确定在418例连续接受治疗的急性淋巴细胞白血病(ALL)患儿中取消初始腰椎穿刺的影响。
患者参加了1989年至1992年在日本中部进行的一项试验。治疗包括标准的四联诱导化疗,随后是基于风险的强化阶段、再诱导化疗、晚期强化和缓解维持治疗(共104周)。初始腰椎穿刺及鞘内注射化疗在泼尼松龙敏感性试验1周后(第8天)进行。终点指标包括对泼尼松龙的反应、第8天腰椎穿刺时的中枢神经系统状态、随后中枢神经系统和骨髓的不良事件以及无事件生存期(EFS)。
缓解诱导率为93.1%,6年EFS率(±SE)为68.7%±2.4%,这与在第0天进行诊断性腰椎穿刺和首次鞘内化疗的患者的历史结果相似。总体而言,84.5%的患者对泼尼松龙反应良好,而15.5%的患者反应较差。反应良好者的临床结局明显更好(6年EFS,74.1%±2.5%,而反应较差者为40.1%±6.4%),这表明省略鞘内化疗并未改变药物敏感性试验的预测价值。18例患者经历中枢神经系统复发作为首个不良事件(累积风险,5.1%;95%置信区间,2.7%至7.4%),这与采用中枢神经系统临床管理常规策略的研究组报告一致。在第8天腰椎穿刺时,29例(占8.1%)出现脑脊液出血,但仅在两例中发现白血病原始细胞。
在ALL患儿中延迟初始腰椎穿刺和鞘内注射化疗似乎是可行的。需要进一步的对照评估来证实这一结论的有效性。